WHO Chemical Risk Assessment Workshop on new and emerging risks to human health from chemicals RIVM is hosting an international workshop on new and emerging risks from chemicals on 20 and 21 February 2019.
Possible health risks due to exposure to chromium-6 at tROM project Tilburg Research by RIVM shows that the participants in the so-called tROM project, their supervisors and other people involved may have been exposed to chromium-6.
Kick off European Project VITAL: Vaccines and InfecTious diseases in the Ageing popuLation Recently, the EU-sponsored Vaccines and InfecTious diseases in the Ageing popuLation (VITAL) project was launched.
Screening for chronic Q-fever is only cost-effective for specific groups RIVM has investigated for which groups screening for chronic Q-fever might be cost-effective.
Pneumococcal disease in the elderly The Health Council of the Netherlands is preparing an advice on pneumococcal vaccination for the elderly on request of the Ministry of Health, Welfare and Sport.
Statement on health care spending Down syndrome Recently a tweet containing a video from a Dutch tv-show about Down syndrome caused a lot of turmoil on Twitter.
Temporary dermal fillers prove harmless RIVM has conducted a market surveillance study of 26 so-called non-permanent fillers. All 26 products proved to be harmless.
Slight increase of the number of tuberculosis patients in 2016 For the second consecutive year, the number of tuberculosis (TB) patients in the Netherlands increased.
Promising biobased alternatives to controversial polar aprotic solvents There are a number of promising biobased alternatives to controversial polar aprotic solvents, as revealed in a report from Wageningen Food & Biobased Research commissioned by RIVM .
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.